KHCM
PCRX icon

Kettle Hill Capital Management’s Pacira BioSciences PCRX Stock Holding History

Kettle Hill Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-77,598
Closed -$2.22M – 53
2024
Q2 		$2.22M Buy
+77,598
New +$2.21M 0.56% 39

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Kettle Hill Capital Management's PCRX Position: Q3 2024 in Review

Kettle Hill Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 77,598 shares — an estimated $2.22M sold.

Kettle Hill Capital Management first reported a position in PCRX in Q2 2024 and held it in 1 quarter. The position peaked at $2.22M in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Kettle Hill Capital Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Kettle Hill Capital Management sold 77,598 Pacira BioSciences shares in Q3 2024, an estimated $2.22M.
  • Kettle Hill Capital Management first reported a position in Pacira BioSciences in Q2 2024 and held it in 1 quarter.
  • Kettle Hill Capital Management's Pacira BioSciences position peaked at $2.22M in Q2 2024.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Kettle Hill Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.